Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Reboxetine
Drug ID BADD_D01919
Description Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.
Indications and Usage For the treatment of clinical depression.
Marketing Status approved; experimental
ATC Code N06AX18
DrugBank ID DB00234
KEGG ID D08472
MeSH ID D000077593
PubChem ID 127151
TTD Drug ID D0N8FQ
NDC Product Code Not Available
UNII 947S0YZ36I
Synonyms Reboxetine | Reboxetine Mesylate | 2-((2-Ethoxyphenoxy)benzyl)morpholine methanesulfonate | Vestra
Chemical Information
Molecular Formula C19H23NO3
CAS Registry Number 71620-89-8
SMILES CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Speech disorder17.02.08.003; 19.19.02.002; 22.12.03.027---
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Tachycardia02.03.02.007---
Tension19.06.02.005---
Testicular disorder21.13.01.002--
Testicular pain21.13.01.005--
Thinking abnormal17.02.05.023; 19.10.03.001---
Tinnitus04.04.01.002; 17.04.07.004--
Tremor17.01.06.002--
Urethral disorder20.07.01.002---
Urethral pain20.02.02.014---
Urinary hesitation20.02.02.009---
Urinary incontinence17.05.01.008; 20.02.02.010--
Urinary retention20.02.02.011--
Urinary tract disorder20.08.01.001---
Urinary tract infection11.01.14.004; 20.08.02.001--
Urine abnormality20.02.01.013---
Urogenital disorder20.08.01.002; 21.10.05.010---
Urticaria10.01.06.001; 23.04.02.001--
Ventricular extrasystoles02.03.04.007---
Vertigo04.04.01.003; 17.02.12.002--
Viral infection11.05.04.001---
Visual impairment06.02.10.013---
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Withdrawal syndrome08.06.02.012; 19.07.06.023---
Left ventricular hypertrophy02.04.02.014---
Hyperuricosuria20.02.01.019---
Rectal tenesmus07.03.03.001; 15.05.03.011---
Nuchal rigidity15.05.04.005; 17.05.02.006---
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages